Markets:

Overview

News

Currencies

International

Treasuries

BioXcel Therapeutics, Inc. - Common Stock (NQ:BTAI)

0.1445 +0.0045 (+3.21%)

Streaming Delayed Price Updated: 11:02 AM EDT, Sep 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioXcel Therapeutics, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022 ↗

December 01, 2022

Via Benzinga

Analyst Ratings for BioXcel Therapeutics ↗

December 01, 2022

Via Benzinga

Is This Soaring Growth Stock a Buy? ↗

November 20, 2022

The answer may depend on your risk tolerance.

Via The Motley Fool

Recap: BioXcel Therapeutics Q2 Earnings ↗

August 09, 2022

BioXcel Therapeutics (NASDAQ:BTAI) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

BioXcel Therapeutics: Q1 Earnings Insights ↗

May 09, 2022

BioXcel Therapeutics (NASDAQ:BTAI) reported its Q1 earnings results on Monday, May 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Oaktree, Qatar Investment Inject $260M In BioXcel To Fund Commercialization Of Schizophrenia Med ↗

April 19, 2022

Via Benzinga

Cramer On This Stock Down 65% Year-To-Date: 'I Do Believe It's Bottoming, But I Don't Know What Gets It Higher' ↗

November 18, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said BioXcel Therapeutics Inc (NASDAQ: BTAI) "may be home run or nothing, and that’s always tough."

Via Benzinga

Twitter Shares Surge Around 8%, Here's 66 Biggest Movers From Yesterday ↗

July 14, 2022

Gainers Qurate Retail, Inc. (NASDAQ: QRTEB) shares climbed 71.1% to close at $5.20. Qurate Retail will host a conference call to discuss Q2 results on Friday, August 5th.

Via Benzinga

Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday ↗

November 11, 2022

Gainers

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022 ↗

July 07, 2022

Upgrades

Via Benzinga

24 Stocks Moving in Thursday's Pre-Market Session ↗

June 02, 2022

Gainers Immix Biopharma, Inc. (NASDAQ: IMMX) rose 42.2% to $2.63 in pre-market trading after declining around 14% on Wednesday. Immix Biopharma, last month, announced positive interim data from an...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

May 25, 2022

Gainers

Via Benzinga

Preview: BioXcel Therapeutics's Earnings ↗

May 06, 2022

BioXcel Therapeutics (NASDAQ:BTAI) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that BioXcel...

Via Benzinga

The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗

May 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates ↗

May 01, 2022

The month of April was a mixed one for regulatory approvals. The Food and Drug Administration delayed approvals for at least three treatment candidates. New molecular entity, or NME, approvals, a...

Via Benzinga

How To Attend BioXcel Therapeutics Q1 2022 Earnings Conference Call ↗

April 27, 2022

BioXcel Therapeutics (NASDAQ:BTAI) will host a conference call at 08:30 AM ET on May 9, 2022, to discuss Q1 2022 earnings results.

Via Benzinga

The Daily Biotech Pulse: Regeneron Acquires Checkmate Pharma, Moderna's Bivalent Booster COVID-19 Vaccine Update, Priority Review For AstraZeneca's Enhertu ↗

April 19, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More ↗

April 10, 2022

Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion.

Via Benzinga

Looking Into Bioxcel Therapeutics Inc's Recent Short Interest ↗

April 07, 2022

Bioxcel Therapeutics Inc's (NASDAQ:BTAI) short percent of float has risen 10.66% since its last report. The company recently reported that it has 1.87 million shares sold short,...

Via Benzinga

Benzinga's Daily Brief On Trending Tickers For April 7, 2022: SDPR S&P 500, Houghton Mifflin, Sunshine Biopharma And More ↗

April 07, 2022

Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news...

Via Benzinga

4 Top Stock Trades for Thursday: MSFT, TWTR, BTAI, PXD ↗

April 06, 2022

Microsoft, Twitter, BioXcel Therapeutics and Pioneer Natural Resources were our top stock trades for Thursday. Here's the trade now.

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

April 06, 2022

Gainers Sunshine Biopharma (NASDAQ:SBFM) shares rose 32.4% to $7.43 during Wednesday's regular session. Sunshine Biopharma's stock is trading at a volume of 46.8...

Via Benzinga

40 Stocks Moving In Wednesday's Mid-Day Session ↗

April 06, 2022

Gainers Advent Technologies Holdings, Inc. (NASDAQ: ADN) shares jumped 77.7% to $3.5950. Advent Technologies and Hyundai Motor Company entered into technology assessment, sales...

Via Benzinga

Why BioXcel Therapeutics Stock Is Surging Today ↗

April 06, 2022

BioXcel Therapeutics Inc (NASDAQ: BTAI) shares are trading higher Wednesday after the company announced that the U.S. Food and Drug Administration approved IGALMI (...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

April 06, 2022

Gainers Healthcare Triangle (NASDAQ:HCTI) stock moved upwards by 17.5% to $1.35 during Wednesday's pre-market session. The company's market cap stands at $47.6...

Via Benzinga

FDA Approves BioXcel's Igalmi - First Orally Dissolving Sublingual Film For Schizophrenia-Associated Agitation ↗

April 06, 2022

The

Via Benzinga

The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy ↗

April 06, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel ↗

April 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight ↗

April 03, 2022

Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates ↗

April 01, 2022

Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with...

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.